Brokerages Expect AnaptysBio Inc (NASDAQ:ANAB) Will Post Quarterly Sales of $6.50 Million

Wall Street analysts forecast that AnaptysBio Inc (NASDAQ:ANAB) will report sales of $6.50 million for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for AnaptysBio’s earnings. The lowest sales estimate is $3.00 million and the highest is $10.00 million. AnaptysBio posted sales of $5.00 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 30%. The firm is scheduled to announce its next earnings results on Thursday, November 14th.

According to Zacks, analysts expect that AnaptysBio will report full-year sales of $8.20 million for the current fiscal year, with estimates ranging from $5.00 million to $15.00 million. For the next financial year, analysts expect that the company will report sales of $7.08 million, with estimates ranging from $5.25 million to $10.00 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side analysts that follow AnaptysBio.

AnaptysBio (NASDAQ:ANAB) last posted its earnings results on Thursday, August 8th. The biotechnology company reported ($0.89) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.97) by $0.08. The firm had revenue of $5.00 million during the quarter. The business’s revenue was up 4900.0% compared to the same quarter last year. During the same quarter last year, the business earned ($0.57) earnings per share.

Several analysts have weighed in on the company. HC Wainwright set a $126.00 target price on AnaptysBio and gave the company a “buy” rating in a report on Monday, June 24th. BidaskClub raised AnaptysBio from a “strong sell” rating to a “sell” rating in a report on Friday. Cantor Fitzgerald set a $140.00 target price on AnaptysBio and gave the company a “buy” rating in a report on Tuesday, August 20th. Stifel Nicolaus reissued a “hold” rating on shares of AnaptysBio in a report on Monday, September 30th. Finally, Zacks Investment Research raised AnaptysBio from a “sell” rating to a “hold” rating in a report on Tuesday. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and seven have given a buy rating to the stock. AnaptysBio presently has a consensus rating of “Buy” and an average price target of $99.63.

AnaptysBio stock opened at $37.04 on Friday. The firm has a market capitalization of $973.17 million, a price-to-earnings ratio of -14.82 and a beta of 1.50. AnaptysBio has a fifty-two week low of $29.43 and a fifty-two week high of $87.49. The stock’s fifty day moving average is $38.54 and its two-hundred day moving average is $57.60.

Several institutional investors and hedge funds have recently bought and sold shares of ANAB. Whittier Trust Co. boosted its position in AnaptysBio by 35.0% during the 3rd quarter. Whittier Trust Co. now owns 5,085 shares of the biotechnology company’s stock valued at $178,000 after purchasing an additional 1,317 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of AnaptysBio by 42.6% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,851 shares of the biotechnology company’s stock valued at $65,000 after purchasing an additional 553 shares during the period. Walleye Trading Advisors LLC acquired a new position in shares of AnaptysBio in the 2nd quarter valued at $270,000. Walleye Trading LLC lifted its stake in shares of AnaptysBio by 297.5% in the 2nd quarter. Walleye Trading LLC now owns 5,500 shares of the biotechnology company’s stock valued at $310,000 after purchasing an additional 8,285 shares during the period. Finally, Nuveen Asset Management LLC acquired a new position in shares of AnaptysBio in the 2nd quarter valued at $5,606,000.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company's products include Etokimab, an anti-interleukin (IL)-33 program for the treatment of atopic dermatitis, eosinophilic asthma, and chronic rhinosinusitis with nasal polyps; ANB019, an anti-IL-36 receptor program for generalized pustular psoriasis and palmo-plantar pustular psoriasis; and anti-inflammatory checkpoint modulators for inflammatory diseases.

Featured Story: Bid-Ask Spread

Get a free copy of the Zacks research report on AnaptysBio (ANAB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for AnaptysBio (NASDAQ:ANAB)

Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.